Secretory leukocyte protease inhibitor as an inhibitor of tryptase
AssigneeMiles Inc.
InventorsDaniel K. Muller, Elise Brownell, Katherine A. Delaria
Life of this patent
Estimating the term…
Abstract
This invention concerns methods of treating mast-cell mediated conditions in mammals, the methods comprising administering to the mammals pharmacologically active fragments or muteins of SLPI; methods of treating asthma or allergic rhinitis in mammals, the methods comprising administering to the mammals SLPI or pharmacologically active fragments or muteins thereof; methods for inhibiting tryptase; methods for identifying inhibitors of tryptase; and certain fragments and muteins of SLPI.
Claims6
A method of treating a mast cell-mediated condition in a mammal, which comprises administering to said mammal an amount of a pharmacologically active fragment of SLPI or mutein thereof which is effective to treat said condition, said fragment or mutein being selected from the group consisting of;
- the amino acid sequences 57-102 and 5-49 of human SLPI;
- the Leu-72-Arg and Leu-72-Lys muteins of the 57-107 and 57-102 sequences of human SLPI;
- the Leu-19-Arg and Leu-19-Lys muteins of the 5-49 sequence of human SLPI;
- the 5-102 sequence of human SLPI and muteins thereof;
- and muteins of a fragment of human SLPI wherein said mutein has the amino acid sequence Ser-Gly-Lys-Ser-Phe-Lys-Ala-Gly-Val-Cys-Pro Lys-Lys-Ser-Ala-Gln-Cys-Xaa-Leu-Arg-Tyr-Lys-Lys-Pro-Glu-Cys-Gln-Ser-Asp-Tr p- Gln-Cys-Pro-Gly-Lys-Lys-Arg-Cys-Cys-Pro-Asp-Thr-Cys-Gly-Ile-Lys-Cys-Leu-As p wherein Xaa is Arg or Lys.
A method of treating the conditions of asthma or allergic rhinitis in a mammal, which comprises administering to said mammal an amount of a pharmacologically active fragment or mutein of SLPI which is effective to treat said conditions, said fragment or mutein being selected from the group consisting of:
- the amino acid sequences 57-102 and 5-49 of human SLPI;
- the Leu-72-Arg and Leu-72-Lys muteins of the 57-107 and 57-102 sequences of human SLPI;
- the Leu-19-Arg and Leu-19-Lys muteins of the 5-49 sequence of human SLPI;
- the 5-102 sequence of human SLPI and muteins thereof;
- and muteins of a fragment of human SLPI wherein said mutein has the amino acid sequence Ser-Gly-Lys-Ser-Phe-Lys-Ala- Gly-Val-Cys-Pro-Lys-Lys-Ser-Ala-Gln-Cys-Xaa-Leu-Arg-Tyr-Lys-Lys-Pro-Glu-Cy s- Gln-Ser-Asp-Trp-Gln-Cys-Pro-Gly-Lys-Lys-Arg-Cys-Cys-Pzo-Asp-Thr-Cys-Gly-Il e-Lys-Cys-Leu-Asp wherein Xaa is Arg or Lys.
A method of inhibiting tryptase, which comprises:
- contacting tryptase with an amount of a pharmacologically active fragment or mutein of SLPI which is effective to inhibit the proteolytic activity of the tryptase, said fragment or mutein being selected from the group consisting of;
- the amino acid sequences 57-102 and 5-49 of human SLPI;
- the Leu-72-Arg and Leu-72-Lys muteins of the 57-107 and 57-102 sequences of human SLPI;
- the Leu-19-Arg and Leu-19-Lys muteins of the 5-49 sequence of human SLPI;
- the 5-102 sequence of human SLPI and muteins thereof;
- and muteins of a fragment of human SLPI wherein said mutein has the amino acid sequence Ser-Gly-Lys-Ser-Phe-Lys-Ala- Gly-Val-Cys-Pro-Lys-Lys-Ser-Ala-Gln-Cys-Xaa-Leu-Arg-Tyr-Lys-Lys-Pro-Glu-Cy s- Gln-Ser-Asp-Trp-Gln-Cys-Pro-Gly-Lys-Lys-Arg-Cys-Cys-Pro-Asp-Thr-Cys-Gly-Il e-Lys-Cys-Leu-Asp wherein Xaa is Arg or Lys.
A peptide selected from the group consisting of the amino acid sequences 57-102 and 5-49 of human SLPI;
- the Leu-72-Arg and Leu-72-Lys muteins of the 57-107 and 57-102 sequences of human SLPI;
- the Leu-19-Arg and Leu-19-Lys muteins of the 5-49 sequence of human SLPI;
- the 5-102 sequence of human SLPI and muteins thereof;
- and muteins of a fragment of human SLPI wherein said mutein has the amino acid sequence Ser-Gly-Lys-Ser-Phe-Lys-Ala-Gly-Val-Cys-Pro- Lys-Lys-Ser-Ala-Gln-Cys-Xaa-Leu-Arg-Tyr-Lys-Lys-Pro-Glu-Cys-Gln-Ser-Asp-Tr p- Gln-Cys-Pro-Gly-Lys-Lys-Arg-Cys-Cys-Pro-Asp-Thr-Cys-Gly-Ile-Lys-Cys-Leu-As p wherein Xaa is Arg or Lys.
Dependencies are inferred from the claim text.